Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "NATCO-Pharma-Limited"

43 News Found

NATCO launches Chlorantraniliprole combination agro products in India
News | October 05, 2022

NATCO launches Chlorantraniliprole combination agro products in India

Both products are broad-spectrum, foliar insecticides used across wide range of crops


NATCO launches Chlorantraniliprole (CTPR) formulated product NATGEN
News | September 26, 2022

NATCO launches Chlorantraniliprole (CTPR) formulated product NATGEN

NATCO estimates the current market size of CTPR containing products in India to be over Rs. 2,000 crore.


NATCO gets CTPR launch approval from Delhi High Court
News | September 21, 2022

NATCO gets CTPR launch approval from Delhi High Court

NATCO is the first company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) for indigenous manufacture of Chlorantraniliprole


NATCO Pharma to sell stake in Nativita and assets of Pharma division
News | September 02, 2022

NATCO Pharma to sell stake in Nativita and assets of Pharma division

NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord


NATCO announces tentative approval to its ANDA for Trabectedin
Drug Approval | August 18, 2022

NATCO announces tentative approval to its ANDA for Trabectedin

According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.


Natco Pharma appoints Dr. Pavan Ganapati Bhat as Executive Director
People | August 10, 2022

Natco Pharma appoints Dr. Pavan Ganapati Bhat as Executive Director

He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years


Natco Pharma consolidated Q1FY23 PAT jumps to Rs. 320.4 Cr
News | August 10, 2022

Natco Pharma consolidated Q1FY23 PAT jumps to Rs. 320.4 Cr

The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.


NATCO launches first generic version of Nexavar Tablets in the US
News | June 01, 2022

NATCO launches first generic version of Nexavar Tablets in the US

The product will be launched by NATCO's commercial partner Viatris.


Johnson & Johnson and Momenta Pharmaceuticals file lawsuit against NATCO Pharma
News | May 25, 2022

Johnson & Johnson and Momenta Pharmaceuticals file lawsuit against NATCO Pharma

This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan


Fifty-five manufacturers selected for Pharma PLI sector
News | November 27, 2021

Fifty-five manufacturers selected for Pharma PLI sector

The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme